Roche Shared Positive Vamikibart Phase III Results
New clinical trial data showed vision improvements for patients with uveitic macular edema.
Updated on Oct. 10, 2026 in Stroke
Live Poll
Do you trust new targeted medical therapies more than traditional long-term steroid treatments for chronic conditions?
Roche has released 52-week data from Phase III clinical trials evaluating the drug vamikibart for the treatment of uveitic macular edema. The results, presented at the American Academy of Ophthalmology meeting, highlight sustained vision improvements and reduced macular thickness.
Why it matters
Vamikibart targets interleukin-6 to treat the inflammatory pathways behind uveitic macular edema, which is the leading cause of severe vision loss in uveitis patients. Addressing this condition early is critical, as approximately 20% of patients currently progress to blindness within three years.
In the MEERKAT and SANDCAT studies, patients were treated with 0.25 mg or 1 mg doses over 52 weeks. About two-thirds of patients required no retreatment after an initial 16-week period.
The players
Roche
This Switzerland-based multinational healthcare company researches and develops diagnostic and therapeutic treatments for various medical conditions.
Food and Drug Administration
This United States federal agency is responsible for protecting public health by regulating the safety, efficacy, and security of pharmaceutical drugs.
The details
The drug functions by targeting interleukin-6 to suppress inflammation in the eye. During the trial, patients received either a sham injection or one of two dosage levels of vamikibart every four weeks for the first 16 weeks, followed by PRN dosing for the remainder of the year.
Timeline
October 2025: 16-week primary analysis results were presented.
October 10, 2026: One-year Phase III data was presented at AAO 2026.
July 2027: The FDA is expected to make an approval decision.
The Big Picture
This development follows the protocols established by the clinical trial registration for MEERKAT study. It marks a significant advancement in using targeted biologic inhibitors to address ocular inflammation compared to traditional steroid-based treatments.
If approved, vamikibart could offer a new option for patients facing vision loss from uveitic macular edema by reducing the frequency of necessary medical treatments. Patients should consult with ophthalmologists regarding current trial availability and how these biologics differ from existing therapies.
The takeaway
Targeted biologic treatments like vamikibart represent a move toward more sustainable management of chronic inflammatory eye conditions. Patients suffering from uveitis should monitor their vision closely and discuss the potential long-term benefits of biologic therapy with their specialists.
What happens next
The FDA is expected to issue a regulatory decision regarding the approval of vamikibart by July 2027.
Further reading
For more information on current treatment trends, visit the Stroke section.
More information
View the clinical trial registration for MEERKAT study for detailed protocol information.
Live Poll
Do you trust new targeted medical therapies more than traditional long-term steroid treatments for chronic conditions?
